https://scholars.lib.ntu.edu.tw/handle/123456789/495129
標題: | A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma | 作者: | Chen Y.-M. CHONG-JEN YU CHIH-HSIN YANG Perng R.-P. Tsai C.-M. Shih J.-F. ANN-LII CHENG Lefresne F. Barbier M. Pouget J.-C. PAN-CHYR YANG |
公開日期: | 2007 | 卷: | 56 | 期: | 1 | 起(迄)頁: | 89-95 | 來源出版物: | Lung Cancer | 摘要: | Background: Intravenous vinorelbine plus cisplatin is widely prescribed for the treatment of NSCLC. The objective of this phase II study was to define the efficacy of an oral form of vinorelbine combined with cisplatin for first line treatment of advanced/metastatic NSCLC. Patients and methods: From September 2002 to December 2003, 46 chemotherapy-naive patients received 80 mg/m2 of cisplatin on day 1 and oral vinorelbine at 60 mg/m2 on days 1 and 8, every 3 weeks. Results: After an independent panel review, the response rate was 37.5 % [95% confidence interval (CI): 22.7-54.2%] in the evaluable population and 32.6% [95% CI: 19.5-48] in the intent-to-treat population. Median progression-free survival was 5.6 months and overall survival was 11.2 months. Grades 3 and 4 neutropenia was observed in 58.7% of patients, with febrile neutropenia and neutropenic infection in 4.3 and 8.7% of patients, respectively. The main non-haematological toxicities were hypotension, fatigue (8.7% for each) and gastrointestinal disorders with rare grades 3 and 4. Conclusions: These results suggest that the combination of cisplatin at 80 mg/m2 on day 1 with oral vinorelbine at 60 mg/m2 on days 1 and 8, every 3 weeks, is an active regimen, associated with acceptable toxicity. Oral vinorelbine is therefore a good alternative to the i.v. formulation. ? 2006 Elsevier Ireland Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847683382&doi=10.1016%2fj.lungcan.2006.11.017&partnerID=40&md5=8820ab0dc51f1d1b0e2596e1df99f1c1 https://scholars.lib.ntu.edu.tw/handle/123456789/495129 |
ISSN: | 0169-5002 | DOI: | 10.1016/j.lungcan.2006.11.017 | SDG/關鍵字: | cisplatin; navelbine; serotonin 2 antagonist; adult; aged; alopecia; anemia; anorexia; article; cancer combination chemotherapy; cancer growth; cancer survival; clinical article; clinical trial; confidence interval; constipation; diarrhea; disease severity; dizziness; drug effect; drug efficacy; drug response; drug withdrawal; fatigue; febrile neutropenia; female; hearing disorder; human; hypotension; infection; insomnia; leukopenia; lung non small cell cancer; male; multicenter study; multiple cycle treatment; nausea; neurotoxicity; neutropenia; neutropenic infection; phase 2 clinical trial; priority journal; side effect; survival rate; survival time; Taiwan; thrombocytopenia; vomiting; weight reduction; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taiwan; Treatment Outcome; Vinblastine |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。